Growth Clinical Trial
— NeHMO DACHOfficial title:
Growth and Feeding Tolerance of Infants Consuming a Formula Supplemented With Human Milk Oligosaccharides (HMOs): An Uncontrolled, Open-label, Prospective Study
Verified date | November 2021 |
Source | Nestlé |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Human milk oligosaccharides (HMOs) represent the third largest solid component of breast milk. Technology advancements made it possible to supplement infant formulas with HMOs (2'FL, LNnT). Two published RCTs have demonstrated that infant formulas supplemented with 2'FL or 2'FL+LNnT are safe, well-tolerated, support normal grow, and may support healthy GI function and confer immune benefits. The performance of HMOs-supplemented formulas assessed in a real-world setting is complementary to previously conducted RCTs conducted in highly controlled clinical settings. Main objectives will be to monitor the safety & tolerance of HMOs-supplemented formulas in larger and diverse infant populations; to assess the performance of HMOs-supplemented formulas in mixed-fed infants, a population that was not studied in previous RCTs but likely represents a relatively common feeding regimen. Finally, considering the potential health/immune benefits of HMOs, it is also important explore the incidences of illnesses (i.e., respiratory illnesses, GI illnesses, and fever) associated with consuming HMOs-supplemented formulas and compare with breastfed infants data.
Status | Completed |
Enrollment | 106 |
Est. completion date | July 24, 2020 |
Est. primary completion date | July 24, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 2 Months |
Eligibility | Inclusion Criteria: - Evidence of personally signed and dated informed consent document indicating that the infant's parent(s) have been informed of all pertinent aspects of the study - Parent(s) are willing and able to fulfill the requirements of the study protocol - Healthy full term (37-42 weeks gestation) infant - Be between post-natal age (Date of Birth = Day 0) 7 days to 2 months - Parent(s) must have independently elected, before enrollment, to formula feed Exclusion Criteria: - Any known intolerance/allergy to cow's milk (formula-fed group only) - systemic disorders (cardiac, respiratory, endocrinological, hematologic, gastointestinal, or other) - conditions requireing infant feedings other than those specified in the protocol - Infants must have been exclusively consuming breast milk since birth, and their parent(s) must have made the decision to continue exclusively breastfeeding until at least 4 month of age |
Country | Name | City | State |
---|---|---|---|
Austria | Facharzt für Kinder- und Jugendheilkunde | Oberwart | |
Germany | Kinder- und Jugensarztpraxis | Berlin | |
Germany | Evangelisches Waldkrankenhaus Spandau | Berlin-Spandau | |
Germany | Facharzt für Säuglings-, Kinder- und Jugendmedizin | Bremen | |
Germany | Facharztpraxis für Kinder- und Jugendmedizin | Burglengenfeld | |
Germany | Praxis Dr. Klee | Bürstadt | |
Germany | Kinderarztpraxis | Düsseldorf | |
Germany | Praxis Al-Radhi | Ehingen | |
Germany | Gemeinschaftspraxis Kinder- und Jugendarztpraxis | Geldern | |
Germany | Kinder und Jugendarztpraxis | Leinfelden-Echterdingen | |
Germany | Kinderarztpraxis Köllges | Mönchengladbach | |
Germany | Kinder- und Jugendärztliche Gemeinschaftspraxis | Oberhausen | |
Germany | Zentrum für Kinder- und Jugendgesundheit | Regensburg | |
Germany | Kinder- und Jugendarztpraxis | Schwabach | |
Germany | Kinder- und Jugendarzt | Viersen | |
Switzerland | Nestlé Research, Société des Produits Nestlé S.A. | Lausanne | |
Switzerland | Global Medical Affairs, Société des Produits Nestlé | Vevey |
Lead Sponsor | Collaborator |
---|---|
Nestlé | Facharzt für Kinder- und Jugendheilkunde Dr. Faustmann, Oberwart, Facharzt für Säuglings-, Kinder- und Jugendmedizin, Bremen, Facharztpraxis für Kinder- und Jugendmedizin Dr. Aulinger, Burglengenfeld, Gemeinschaftspraxis Kinder- und Jugendpraxis Dr. Stepan Dreher und Tina Hübler, Geldern, Global Medical Affairs, Société des Produits Nestlé S.A., Vevey, Switzerland, Kinder und Jugendarztpraxis Dr. Maier, Leinfelden-Echterdingen, Kinder- und Jugendarzt Dr. Umpfenbach und Dr. Lorenz, Viersen, Kinder- und Jugendärztliche Gemeinschaftspraxis Bedikian & Bouikidis, Oberhausen, Kinder- und Jugendarztpraxis Dr. Kröckel, Dr. Ciesla, Berlin, Kinder- und Jugendarztpraxis Schwabach, Kinderarztpraxis Dr. Zakarian, Düsseldorf, Kinderarztpraxis Köllges, Mossakowski und Meyer-Krott, Mönchengladbach, Nestlé Research, Société des Produits Nestlé S.A., Lausanne, Switzerland, Praxis Al-Radhi, Ehingen, Praxis Dr. Klee, Bürstadt, Waldkrankenhaus Protestant Hospital, Spandau, Zentrum für Kinder- und Jugendgesundheit Regensburg |
Austria, Germany, Switzerland,
Storm HM, Shepard J, Czerkies LM, Kineman B, Cohen SS, Reichert H, Carvalho R. 2'-Fucosyllactose Is Well Tolerated in a 100% Whey, Partially Hydrolyzed Infant Formula With Bifidobacterium lactis: A Randomized Controlled Trial. Glob Pediatr Health. 2019 Mar 15;6:2333794X19833995. doi: 10.1177/2333794X19833995. eCollection 2019. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | World Health Organization (WHO) based weight-for-age z-scores | Weight-for-age z-scores using WHO growth standards | 8 weeks (study end) | |
Primary | World Health Organization (WHO) based length-for-age z-scores | Length-for-age z-scores using WHO growth standards | 8 weeks (study end) | |
Primary | World Health Organization (WHO) head-circumference-for-age z-scores | head-circumference-for-age z-scores using WHO growth standards | 8 weeks (study end) | |
Primary | World Health Organization (WHO) based body-mass-index (BMI)-for-age z-scores | Weight and height will be combined to calculate BMI in kg/m^2, then BMI-for-age z-scores will be derived using WHO growth standards | 8 weeks (study end) | |
Primary | Feeding tolerance | The Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score will be used to assess GI distress. This is a validated 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress. A composite IGSQ score is derived from summing the individual scores with a possible range of 13 to 65 where higher values indicate greater GI distress and values =23 indicate no digestive distress | 4 weeks (study midpoint) | |
Primary | Feeding tolerance | The Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score will be used to assess GI distress. This is a validated 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress. A composite IGSQ score is derived from summing the individual scores with a possible range of 13 to 65 where higher values indicate greater GI distress and values =23 indicate no digestive distress | 8 weeks (study end) | |
Secondary | Formula acceptability | Study Formula Satisfaction Questionnaire | 4 weeks (study midpoint), 8 weeks (study end) | |
Secondary | Standard adverse events (AEs) reporting for safety assessment | Reported adverse events (AEs) and Serious Adverse Events (SAEs) include type, incidence, severity, seriousness and relation to feeding | From the time the informed consent form has been signed at enrollment infant age less than 7 days to 2 months through the 8 weeks of intervention | |
Secondary | Weight | Weight measurements in grams | 8 weeks (study end) | |
Secondary | Length | Length measurements in centimeters | 8 weeks (study end) | |
Secondary | Head circumference | Head circumference measurements in centimeters | 8 weeks (study end) | |
Secondary | Body-mass-index (BMI) | Weight and height will be combined to report BMI in kg/m^2 | 8 weeks (study end) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05551975 -
Preterm Infants Fed a Human Milk Fortifier
|
N/A | |
Completed |
NCT01162798 -
Preterm Infant Growth
|
N/A | |
Completed |
NCT01721512 -
The Growth and Development of Breast and Formula Fed Term Asian Infants
|
N/A | |
Active, not recruiting |
NCT00970398 -
Effect of an Infant Formula on Infant Growth, Health and Immune Functions
|
N/A | |
Completed |
NCT01666457 -
Impact of Implementing an Infant Driven Feeding Program on Oral Feeding and Growth Outcomes of Medically Fragile Infants in the Neonatal ICU (NICU)
|
||
Completed |
NCT00808756 -
Study on Fermentable Carbohydrates in Healthy Infants
|
N/A | |
Completed |
NCT00997971 -
Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein
|
Phase 3 | |
Completed |
NCT03276663 -
Growth of Healthy Term Infants Fed a Partially Hydrolyzed Follow-up Formula
|
N/A | |
Recruiting |
NCT02695784 -
Probiotics After Discharge
|
Phase 4 | |
Withdrawn |
NCT02860026 -
Growth and Tolerance of Healthy Term Infants Fed Cow's Milk-Based Infant Formulas
|
N/A | |
Completed |
NCT01128517 -
Maternal Education on Complementary Feeding and Infant Outcome
|
N/A | |
Completed |
NCT00282113 -
Effects of Probiotic and Prebiotic Combinations on Premature Infants
|
N/A | |
Completed |
NCT03276884 -
Growth and Tolerance of Young Infants
|
N/A | |
Completed |
NCT04055363 -
Human Milk Oligosaccharides (HMOs) Post-market Study on Infants
|
N/A | |
Completed |
NCT05302427 -
Infant Massage and Infant Growth, Mother-Infant Attachment, and Maternal Self-Confidence
|
N/A | |
Not yet recruiting |
NCT05616117 -
Next-generation Effects of Vitamin D Supplementation in Pregnancy
|
||
Active, not recruiting |
NCT02410057 -
Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula
|
N/A | |
Completed |
NCT01158352 -
Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children
|
N/A | |
Completed |
NCT01210391 -
Growth of Infants Fed an Extensively Hydrolyzed Infant Formula
|
N/A | |
Completed |
NCT01109849 -
Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth
|
Phase 4 |